Cargando…
Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges
It is estimated that over 200 million adults worldwide have osteoporosis, a disease that has increasing socioeconomic impact reflected by unsustainable costs associated with disability, fracture management, hospital stays, and treatment. Existing therapeutic treatments for osteoporosis are associate...
Autores principales: | MacNabb, Claire, Patton, D., Hayes, J. S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4899597/ https://www.ncbi.nlm.nih.gov/pubmed/27313945 http://dx.doi.org/10.1155/2016/6217286 |
Ejemplares similares
-
Osteoporosis Treatment with Anti-Sclerostin Antibodies—Mechanisms of Action and Clinical Application
por: Rauner, Martina, et al.
Publicado: (2021) -
Anti-Sclerostin Antibodies in Osteoporosis and Other Bone Diseases
por: Fabre, Stéphanie, et al.
Publicado: (2020) -
Sclerostin Inhibition in the Management of Osteoporosis
por: Appelman-Dijkstra, Natasha M., et al.
Publicado: (2016) -
Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis
por: Shah, Arti D, et al.
Publicado: (2015) -
Sclerostin Inhibition: A Novel Target for the Treatment of Postmenopausal Osteoporosis
por: Aditya, Suruchi, et al.
Publicado: (2021)